$IMUX
Immunic Inc

2014 Q2 Form 10-Q Financial Statement

#000119312514215136 Filed on May 28, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.510M $2.660M $2.590M
YoY Change -0.79% 78.52% 133.33%
% of Gross Profit
Research & Development $9.125M $9.219M $7.650M
YoY Change 101.08% 168.62% 221.43%
% of Gross Profit
Depreciation & Amortization $246.0K $297.0K $230.0K
YoY Change 41.38% 82.21% 130.0%
% of Gross Profit
Operating Expenses $11.64M $11.88M $10.25M
YoY Change 64.77% 141.09% 193.64%
Operating Profit -$11.64M -$11.88M
YoY Change 64.77% 141.09%
Interest Expense $10.00K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.471M $1.128M $10.00K
YoY Change 60.07% -125.45% -99.68%
Pretax Income -$10.17M -$10.75M -$10.24M
YoY Change 65.64% 14.85% 2525.64%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.17M -$10.75M -$10.24M
YoY Change 65.48% 14.85% 2525.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$28.25M -$20.28M -$19.32M
COMMON SHARES
Basic Shares Outstanding 21.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.80M $46.00M $38.20M
YoY Change 119.32% 183.95%
Cash & Equivalents $90.84M $46.04M $38.19M
Short-Term Investments
Other Short-Term Assets $2.600M $6.200M $5.700M
YoY Change 13.04% 675.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $93.49M $52.26M $43.86M
YoY Change 113.45% 207.44%
LONG-TERM ASSETS
Property, Plant & Equipment $3.264M $3.081M $2.467M
YoY Change 81.33% 156.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $263.0K $263.0K $263.0K
YoY Change 31.5%
Total Long-Term Assets $3.527M $3.344M $2.730M
YoY Change 76.35% 178.67%
TOTAL ASSETS
Total Short-Term Assets $93.49M $52.26M $43.86M
Total Long-Term Assets $3.527M $3.344M $2.730M
Total Assets $97.02M $55.61M $46.59M
YoY Change 111.83% 205.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.461M $1.325M $1.224M
YoY Change -43.81% 10.42%
Accrued Expenses $5.806M $5.496M $3.253M
YoY Change 205.58% 587.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.561M $8.633M $7.446M
YoY Change -16.91% 19.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $292.0K $279.0K $321.0K
YoY Change
Total Long-Term Liabilities $292.0K $279.0K $321.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.561M $8.633M $7.446M
Total Long-Term Liabilities $292.0K $279.0K $321.0K
Total Liabilities $7.853M $8.912M $7.767M
YoY Change -13.7% 23.78%
SHAREHOLDERS EQUITY
Retained Earnings -$124.1M -$103.2M
YoY Change
Common Stock $2.000K $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $89.16M -$58.02M -$44.66M
YoY Change
Total Liabilities & Shareholders Equity $97.02M $55.61M $46.59M
YoY Change 111.83% 205.54%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q4
OPERATING ACTIVITIES
Net Income -$10.17M -$10.75M -$10.24M
YoY Change 65.48% 14.85% 2525.38%
Depreciation, Depletion And Amortization $246.0K $297.0K $230.0K
YoY Change 41.38% 82.21% 130.0%
Cash From Operating Activities -$9.880M -$9.360M -$10.14M
YoY Change 68.89% 105.26% 174.05%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K $809.0K -$300.0K
YoY Change -45.45% 574.17% 500.0%
Acquisitions
YoY Change
Other Investing Activities -$230.0K -$40.00K -$220.0K
YoY Change -104.93% -100.99% -98.43%
Cash From Investing Activities -$470.0K -$850.0K -$520.0K
YoY Change -111.08% -121.68% -96.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.14M 18.07M 17.69M
YoY Change 72.85% 682.25% 58.37%
NET CHANGE
Cash From Operating Activities -9.880M -9.360M -10.14M
Cash From Investing Activities -470.0K -850.0K -520.0K
Cash From Financing Activities 55.14M 18.07M 17.69M
Net Change In Cash 44.79M 7.860M 7.030M
YoY Change 47.87% 370.66% -206.84%
FREE CASH FLOW
Cash From Operating Activities -$9.880M -$9.360M -$10.14M
Capital Expenditures -$240.0K $809.0K -$300.0K
Free Cash Flow -$9.640M -$10.17M -$9.840M
YoY Change 78.19% 117.29% 169.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Share Price
SharePrice
7.55
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21790745 shares
CY2013Q1 us-gaap Share Price
SharePrice
6.85
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6152000
CY2013Q1 vtl Deemed Dividend
DeemedDividend
0
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
606238 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3143565 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
606238 shares
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19488134 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2014Q1 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
16009423 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.52
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3143565 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
84500 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.52
CY2014Q1 us-gaap Share Price
SharePrice
11.30
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3134810 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.52
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
29250000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
95.21
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5496000
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6052000
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
124000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
55803000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1325000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8633000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
95000
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
915000
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
279000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-58016000
CY2014Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
279000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
CY2014Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
139000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55608000
CY2014Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
340000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Assets Current
AssetsCurrent
52264000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1007000
CY2014Q1 us-gaap Assets
Assets
55608000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14989210
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46041000
CY2014Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9133000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15025431
CY2014Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
113914000
CY2014Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
3935000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1281000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15025431
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4500000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3081000
CY2014Q1 vtl Accrued Financing Costs Current
AccruedFinancingCostsCurrent
672000
CY2014Q1 vtl Working Capital Amount
WorkingCapitalAmount
43600000
CY2014Q1 vtl Preferred Stock Shares Authorized But Undesignated
PreferredStockSharesAuthorizedButUndesignated
4498599 shares
CY2014Q1 vtl Deemed Dividend
DeemedDividend
22000
CY2014Q1 vtl Future Purchase Rights Liabilities Current
FuturePurchaseRightsLiabilitiesCurrent
1472000
CY2014Q1 vtl Accrued Clinical Costs
AccruedClinicalCosts
3785000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4477000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
606238 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
606238 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.71
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3098573 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
29250000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3253000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5755000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58413000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1224000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
142000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46585000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
369000
CY2013Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
3506000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1200000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2467000
CY2013Q4 vtl Accrued Financing Costs Current
AccruedFinancingCostsCurrent
496000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7446000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
96000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
512000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
321000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-44657000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
321000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
43855000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
963000
CY2013Q4 us-gaap Assets
Assets
46585000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38186000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8222000
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
103166000
CY2013Q4 vtl Preferred Stock Shares Authorized But Undesignated
PreferredStockSharesAuthorizedButUndesignated
4498599 shares
CY2013Q4 vtl Future Purchase Rights Liabilities Current
FuturePurchaseRightsLiabilitiesCurrent
2600000
CY2013Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2067000
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y29D
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.850 pure
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0038 pure
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 vtl Common Stock Fair Value Per Share
CommonStockFairValuePerShare
5.93
CY2013 vtl Preferred Stock Fair Value Per Share
PreferredStockFairValuePerShare
8.00
CY2013 vtl Fair Value Assumptions Number Of Nodes
FairValueAssumptionsNumberOfNodes
25 Nodes
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-103880000
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3265000 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1295000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113819000
us-gaap Gross Profit
GrossProfit
9000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
16991000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
774000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
269000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2154000
us-gaap Investment Income Interest
InvestmentIncomeInterest
769000
us-gaap Profit Loss
ProfitLoss
-113914000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
83000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome
5000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
95000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
18000
us-gaap Operating Income Loss
OperatingIncomeLoss
-116161000
us-gaap Interest Paid
InterestPaid
518000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2242000
us-gaap Net Income Loss
NetIncomeLoss
-125738000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
33996000
us-gaap Sales Revenue Net
SalesRevenueNet
22000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5478000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1007000
us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple
-113919000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
130884000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
140000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43972000
us-gaap Paid In Kind Interest
PaidInKindInterest
13517000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
88000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
156169000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
64083000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
11738000
us-gaap Share Based Compensation
ShareBasedCompensation
1762000
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
86000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46041000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6336000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4813000
us-gaap Interest Expense
InterestExpense
14298000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
502000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72198000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
334000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6283000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
30277000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
17000000
us-gaap Operating Expenses
OperatingExpenses
116170000
vtl Deferred Financing Costs
DeferredFinancingCosts
3461000
vtl Value Of Rights Of Possible Future Issuances
ValueOfRightsOfPossibleFutureIssuances
4395000
vtl Proceeds From Stock Options Early Exercised
ProceedsFromStockOptionsEarlyExercised
227000
vtl Gain Loss On Re Measurement Of Preferred Stock Warrant Liability
GainLossOnReMeasurementOfPreferredStockWarrantLiability
-12584000
vtl Leasehold Improvements Paid By Landlord
LeaseholdImprovementsPaidByLandlord
478000
vtl Beneficial Conversion Value For Preferred Stock
BeneficialConversionValueForPreferredStock
969000
vtl Gain Loss On Revaluation Of Preferred Stock Warrant Liabilities
GainLossOnRevaluationOfPreferredStockWarrantLiabilities
12579000
vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
2923000
vtl Capital Expenditures Incurred Through Debt
CapitalExpendituresIncurredThroughDebt
2807000
vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
730000
vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
79000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
467167 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4555000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.008 pure
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
216000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9355000
CY2013Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1000000
CY2013Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.94
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-22.11
CY2013Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.000 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0020 pure
CY2013Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-9358000
CY2013Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
13000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4926000
CY2013Q1 us-gaap Interest Paid
InterestPaid
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4432000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10331000
CY2013Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120000
CY2013Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-37000
CY2013Q1 us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple
-9358000
CY2013Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2311000
CY2013Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1494000
CY2013Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
3000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2311000
CY2013Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2013Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
970000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
105000
CY2013Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
3000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
163000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1675000
CY2013Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
139000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3916000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
247000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3432000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
163000
CY2013Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
CY2013Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
4999000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
4926000
CY2013Q1 vtl Deferred Financing Costs
DeferredFinancingCosts
CY2013Q1 vtl Value Of Rights Of Possible Future Issuances
ValueOfRightsOfPossibleFutureIssuances
672000
CY2013Q1 vtl Proceeds From Stock Options Early Exercised
ProceedsFromStockOptionsEarlyExercised
CY2013Q1 vtl Gain Loss On Re Measurement Of Preferred Stock Warrant Liability
GainLossOnReMeasurementOfPreferredStockWarrantLiability
CY2013Q1 vtl Leasehold Improvements Paid By Landlord
LeaseholdImprovementsPaidByLandlord
CY2013Q1 vtl Beneficial Conversion Value For Preferred Stock
BeneficialConversionValueForPreferredStock
CY2013Q1 vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
-4434000
CY2013Q1 vtl Capital Expenditures Incurred Through Debt
CapitalExpendituresIncurredThroughDebt
CY2013Q1 vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y10M2D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y6M26D
CY2014Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.800 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
61653 shares
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M26D
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
564186 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.00
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9364000
CY2014Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
All outstanding junior and senior preferred stock was converted into common stock on a one to one basis
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.17
CY2014Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0036 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-24.49
CY2014Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
16661 shares
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
297000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.810 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M26D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0013 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.03
CY2014Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
CY2014Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
11876000
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</p> </div>
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10749000
CY2014Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.016 pure
CY2014Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
102000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2014Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2014Q1 us-gaap Profit Loss
ProfitLoss
-10748000
CY2014Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
45000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11876000
CY2014Q1 us-gaap Interest Paid
InterestPaid
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1128000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-13818000
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
809000
CY2014Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
44000
CY2014Q1 us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple
-10748000
CY2014Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18167000
CY2014Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2657000
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
18073000
CY2014Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
3048000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
435000
CY2014Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
22000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
297000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7855000
CY2014Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
183000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-853000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1964000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9219000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2014Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
CY2014Q1 vtl Deferred Financing Costs
DeferredFinancingCosts
94000
CY2014Q1 vtl Common Stock Fair Value Per Share
CommonStockFairValuePerShare
11.30
CY2014Q1 vtl Value Of Rights Of Possible Future Issuances
ValueOfRightsOfPossibleFutureIssuances
CY2014Q1 vtl Proceeds From Stock Options Early Exercised
ProceedsFromStockOptionsEarlyExercised
CY2014Q1 vtl Gain Loss On Re Measurement Of Preferred Stock Warrant Liability
GainLossOnReMeasurementOfPreferredStockWarrantLiability
CY2014Q1 vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
CY2014Q1 vtl Beneficial Conversion Value For Preferred Stock
BeneficialConversionValueForPreferredStock
CY2014Q1 vtl Preferred Stock Fair Value Per Share
PreferredStockFairValuePerShare
8.00
CY2014Q1 vtl Operating Lease Agreements Expiration Year
OperatingLeaseAgreementsExpirationYear
2017
CY2014Q1 vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
1128000
CY2014Q1 vtl Fair Value Assumptions Number Of Nodes
FairValueAssumptionsNumberOfNodes
22 Nodes
CY2014Q1 vtl Capital Expenditures Incurred Through Debt
CapitalExpendituresIncurredThroughDebt
CY2014Q1 vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
336000
CY2014Q1 vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
26000

Files In Submission

Name View Source Status
0001193125-14-215136-index-headers.html Edgar Link pending
0001193125-14-215136-index.html Edgar Link pending
0001193125-14-215136.txt Edgar Link pending
0001193125-14-215136-xbrl.zip Edgar Link pending
d711893d10q.htm Edgar Link pending
d711893dex311.htm Edgar Link pending
d711893dex312.htm Edgar Link pending
d711893dex321.htm Edgar Link pending
d711893dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20140331.xml Edgar Link completed
vtl-20140331.xsd Edgar Link pending
vtl-20140331_cal.xml Edgar Link unprocessable
vtl-20140331_def.xml Edgar Link unprocessable
vtl-20140331_lab.xml Edgar Link unprocessable
vtl-20140331_pre.xml Edgar Link unprocessable